A retrospective, multicenter study of the efficacy of lapatinib plus trastuzumab in HER2-positive metastatic breast cancer patients previously treated with trastuzumab, lapatinib, or both: the Trastyvere study

被引：0
|
作者：
J. Gavilá
J. De La Haba
B. Bermejo
Á. Rodríguez-Lescure
A. Antón
E. Ciruelos
J. Brunet
E. Muñoz-Couselo
M. Santisteban
C. A. Rodríguez Sánchez
A. Santaballa
P. Sánchez Rovira
J. Á. García Sáenz
M. Ruiz-Borrego
A. L. Guerrero-Zotano
M. Huerta
A. Cotes-Sanchís
J. Lao Romera
E. Aguirre
J. Cortés
A. Llombart-Cussac
机构：
[1] Instituto Valenciano de Oncología,Medical Oncology Department
[2] Hospital Reina Sofía,Medical Oncology Department
[3] Hospital Clínico Valencia,Medical Oncology Department
[4] Hospital General Elche,Medical Oncology Department
[5] Hospital Miguel Servet,Medical Oncology Department
[6] Hospital 12 de Octubre,Medical Oncology Department
[7] Institut Català D’Oncologia,Medical Oncology Department
[8] Hospital Universitari Vall d’Hebron,Medical Oncology Department
[9] Clínica Universidad de Navarra,Medical Oncology Department
[10] Hospital Universitario de Salamanca - IBSAL,Medical Oncology Department
[11] Hospital Universitari i Politècnic La Fe,Medical Oncology Department
[12] Complejo Hospitalario de Jaén,Medical Oncology Department
[13] Hospital Clínico San Carlos,Medical Oncology Department
[14] Hospital Universitario Virgen del Rocío,Medical Oncology Department
[15] Hospital de Día QuirónSalud,Medical Oncology Department
[16] Vall d’Hebron Institute of Oncology (VHIO),Medical Oncology Department
[17] IOB,undefined
[18] Institute of Oncology,undefined
[19] QuirónSalud Group,undefined
[20] Medica Scientia Innovation Research (MedSIR),undefined
[21] Hospital Arnau de Vilanova - FISABIO,undefined
来源：
Clinical and Translational Oncology | 2020年 / 22卷
关键词：
Human epidermal growth factor receptor 2 positive; Metastatic breast cancer; Lapatinib; Trastuzumab; Dual HER2 blockade; Tyrosine kinase inhibitor;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：420 / 428
页数：8
相关论文
共 50 条
  • [1] A retrospective, multicenter study of the efficacy of lapatinib plus trastuzumab in HER2-positive metastatic breast cancer patients previously treated with trastuzumab, lapatinib, or both: the Trastyvere study
    Gavila, J.
    De La Haba, J.
    Bermejo, B.
    Rodriguez-Lescure, A.
    Anton, A.
    Ciruelos, E.
    Brunet, J.
    Munoz-Couselo, E.
    Santisteban, M.
    Rodriguez Sanchez, C. A.
    Santaballa, A.
    Sanchez Rovira, P.
    Garcia Saenz, J. a.
    Ruiz-Borrego, M.
    Guerrero-Zotano, A. L.
    Huerta, M.
    Cotes-Sanchis, A.
    Lao Romera, J.
    Aguirre, E.
    Cortes, J.
    Llombart-Cussac, A.
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2020, 22 (03): : 420 - 428
  • [2] TRASTYVERE study: A retrospective analysis of HER2-positive metastatic breast cancer (MBC) patients treated in Spain with lapatinib (L) plus trastuzumab (T)
    Gavila, Joaquin
    Bermejo, Begona
    Rodriguez-Lescure, Alvaro
    Lao Romera, Juan
    Manso, Luis
    Brunet, Joan
    Munoz, Eva
    Santisteban, Marta
    Rodriguez, Cesar A.
    Santaballa, Ana
    de la Haba, Juan
    Sanchez-Rovira, Pedro
    Ruiz-Borrego, Manuel
    Angel Garcia-Saenz, Jose
    Cortes, Javier
    Llombart, Antonio
    CANCER RESEARCH, 2015, 75
  • [3] Trastuzumab-Emtansine versus Capecitabine plus Lapatinib in Patients with previously treated HER2-positive metastatic Breast Cancer
    Ruckhaeberle, Eugen
    ONKOLOGE, 2017, 23 (11): : 940 - 942
  • [4] Preliminary results from TRASTYVERE study: A retrospective analysis of heavily pretreated HER2-positive metastatic breast cancer patients treated in Spain with lapatinib plus trastuzumab as compassive therapy
    Gavila, J.
    Bermejo, B.
    Manso, L.
    Munoz, E.
    Anton, A.
    Brunet, J.
    Rodriguez, C. A.
    Santaballa, A.
    Cortes, J.
    Llombart, A.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 : S181 - S181
  • [5] Preliminary results from TRASTYVERE study: A retrospective analysis of HER2-positive (HER2) metastatic breast cancer (MBC) patients treated in Spain with lapatinib (L) plus trastuzumab (T).
    Gavila, Joaquin
    Bermejo, Begona
    Manso, Luis
    Munoz, Eva
    Anton, Antonio
    Brunet, Joan
    Rodriguez-Lescure, Alvaro
    Augusto Rodriguez, Cesar
    Santaballa, Ana
    Sanchez-Rovira, Pedro
    de la Haba-Rodriguez, Juan
    Santisteban, Marta
    Ruiz Borrego, Manuel
    Cortes, Javier
    Llombart-Cussac, Antonio
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [6] Lapatinib with trastuzumab for heavily treated HER2-positive metastatic breast cancer (mBC).
    Sotelo, Miguel J.
    Manso, Luis
    Garcia Saenz, Jose Angel
    Ciruelos, Eva M.
    Moreno, Fernando
    Mendiola, Cesar
    Callata, Hector
    Ghanem, Ismael
    Cabezas, Santiago
    Gonzalez-Larriba, Jose-Luis
    Diaz Rubio, Eduardo
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [7] Pyrotinib Plus Vinorelbine Versus Lapatinib Plus Capecitabine in Patients With Previously Treated HER2-Positive Metastatic Breast Cancer: A Multicenter, Retrospective Study
    Xie, Yizhao
    Li, Yi
    Ting, Luo
    Sang, Die
    Yuan, Peng
    Li, Wei
    Li, Huihui
    Ge, Rui
    Wang, Biyun
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [8] Trastuzumab and lapatinib in HER2-positive metastatic colorectal cancer
    Biswas, Bivas
    Rastogi, Sameer
    Batra, Atul
    Ganguly, Sandip
    NATIONAL MEDICAL JOURNAL OF INDIA, 2016, 29 (04): : 219 - 220
  • [9] Real-world data of lapatinib and treatment after lapatinib in patients with previously treated HER2-positive metastatic breast cancer: A multicenter, retrospective study
    Xie, Yizhao
    Ge, Rui
    Sang, Die
    Luo, Ting
    Li, Wei
    Ji, Xuening
    Yuan, Peng
    Wang, Biyun
    CANCER MEDICINE, 2020, 9 (09): : 2981 - 2988
  • [10] Pyrotinib plus trastuzumab versus pertuzumab plus trastuzumab in patients with HER2-positive metastatic breast cancer: A multicenter, retrospective study
    Wang, B.
    You, S.
    Xie, Y.
    Xu, F.
    Sang, D.
    Luo, T.
    Yuan, P.
    ANNALS OF ONCOLOGY, 2023, 34 : S361 - S362
12345